*Disseminated on Behalf of Medicus Pharma Ltd. Please see disclosures below. |
| "MDCX" Redefines Basel Cell Carcinoma Care |
| | | | | Folks, I hope you are ready, because we've got another juicy idea for you today! Medicus Pharma (MDCX) is a life sciences company that's aiming to do something bold in the world of oncology. At its core, Medicus is built around a clear mission: accelerate the clinical development and commercialization of novel, de-risked therapeutic assets. Translation? They find high-potential treatments—ones already showing signs of effectiveness—and push them toward the finish line. | | | Their lead asset is SkinJect—a needle-free, non-invasive pharmaceutical delivery patch designed to treat Basal Cell Carcinoma (BCC), the most common form of skin cancer in the U.S., affecting more than 5 million Americans annually. But SkinJect isn't just a "nice idea"—it's a full-blown platform opportunity, and MDCX is already knee-deep in an FDA-reviewed Phase II trial. The company holds exclusive worldwide rights to this tech through agreements with Carnegie Mellon and the University of Pittsburgh, and they're building a case for SkinJect as the next big alternative to painful, scarring surgeries like Mohs. Let's break down a few reasons why Medicus deserves a closer look: 1. Strong Clinical Momentum Backed by Real-World Data MDCX isn't in the idea stage—they're executing. After completing a Phase I trial in 2021, Medicus submitted a Phase II IND to the FDA in early 2024 and began recruiting patients across nine U.S. sites in August 2024. That trial has since expanded to include up to 90 patients, with more than 50% already enrolled. | | | In Q1 2025, interim data revealed over 60% complete clinical clearance—a result that generated serious validation. And more progress is around the corner: a Type C meeting with the FDA is scheduled for Q4 2025, which will take place following the interim readout to inform next steps with regulators. This isn't a pipeline on pause—it's a clinical program in motion, with eyes on a pivotal trial in 2026 and a potential FDA submission by 2027!
2. Real Competitive Advantages Where It Matters
SkinJect's microneedle delivery approach is doing more than replacing scalpels—it's building a new standard. - Cost: Estimated at ~$1,000 for a full treatment vs. up to $15,000 for surgery
- Time to treatment: Same-day use possible, while Mohs surgery can involve 2–8 month wait time
- User experience: High patient and physician acceptance, minimal irritation, and no scarring compared to typical lumpy post-surgical results
| | | On the treatment matrix shown in the company's own clinical comparisons, SkinJect scores high on efficacy, convenience, and price—all the categories that drive market adoption. 3. IP Protection and Platform Potential Medicus holds exclusive worldwide rights to the SkinJect technology, including patents that run through 2035. These cover both the microneedle composition and its transdermal pharmaceutical delivery mechanism. But this isn't just about BCC. The company is already preparing follow-on INDs for conditions like Actinic Keratosis, Squamous Cell Carcinoma in situ, and even Equine Squamous Cell Carcinoma. 4. Experienced Leadership with a Playbook for Execution The leadership team is packed with medical, scientific, and public company experience. CEO Dr. Raza Bokhari leads a seasoned team with backgrounds in oncology, capital markets, pharma development, and biotech operations. | | | And it's not just internal confidence—Medicus is gaining outside recognition too. The company ranked #7 in 360iResearch's Strategic Positioning Matrix among major players in the global BCC treatment space, competing in the same field as pharma giants like Regeneron, Bausch, and Roche. Of course, it's important to keep in mind that small caps inherently carry risk, and nothing is guaranteed in this space. But between strong clinical progress, IP-backed tech, and a truly differentiated approach, Medicus Pharma (MDCX) stands out as one of the more compelling small-cap pharma stories on the board right now. Anyways... That's all for now! Until next time,
-Damian | P.S. Want our text alerts? Text "ZIPTRADER" to 1-(855)-228-1598 to sign up!
(standard carrier data/text rates apply) |
|
|
|---|
|
*Disseminated on Behalf of Medicus Pharma Ltd. Please see disclosures below. |
|
|---|
|
| | 5101 SANTA MONICA BLVD STE 8 #62, 90029, LOS ANGELES, CA |
| You've received it because you've subscribed to our newsletter or are a member of ZipTraderU. |
| This email was sent to punjabsvera@gmail.com |
| *SPONSORED CONTENT* ZipTrader LLC is a publishing company, we are not financial advisors. This is not financial advice. Investments involve risk and are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance. ZipTrader has been compensated thirty-eight thousand USD by ACH Bank Transfer by TD Media LLC, who received funds from Awareness Consulting Network LLC, who received funds from Razor Pitch Inc, who received funds from Medicus Pharma Ltd, to distribute media via email, SMS, and YouTube for Medicus Pharma Ltd (MDCX) from August 14, 2025 to August 22, 2025. ZipTrader has been compensated thirty-seven thousand five hundred USD by ACH Bank Transfer by TD Media LLC, who received funds from Awareness Consulting Network LLC, to distribute media via email, SMS, and YouTube for Medicus Pharma Ltd (MDCX) from July 8, 2025 to July 10, 2025. The reader should assume that paying parties, clients of paying parties, and third parties may own shares and may sell shares during or after this campaign, which could negatively impact the stock price. ZipTrader may receive additional campaigns in the future by TD Media LLC to distribute media for Medicus Pharma Ltd (MDCX). As a result of this advertisement and other marketing efforts, ZipTrader may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of this advertisement, the owners of ZipTrader do not hold a position in Medicus Pharma Ltd (MDCX). This advertisement and other marketing efforts may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Medicus Pharma Ltd (MDCX), increased trading volume, and possibly an increased share price of Medicus Pharma Ltd (MDCX), which may or may not be temporary and decrease once the marketing arrangement has ended. |
| BY READING THIS EMAIL & ALL ZIPTRADER CONTENT YOU AGREE: This is not financial advice. You must do your own due diligence on all information. ZIPTRADER LLC is a publishing company and we provide general information, opinions, & news coverage to viewers. However – we do not provide personalized financial advice, are not financial advisors, and our opinions are not suitable for all investors. You should not treat any opinion as expressed as a specific inducement to make a particular investment or follow a particular strategy, but just as an opinion. Use at your own risk. Past Performance is not indicative of future results, and any results presented are not typical, and should not be understood as typical. Actual results vary given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. TRADING IS RISKY: Most traders in all markets lose all of their money (and more if they use margin). Most small businesses fail. Do NOT partake in trading, investing, entrepreneurship or any other risky endeavor covered here if you are not prepared with the reality that most fail. We reserve the right to have affiliate relationships with advertisers/sponsors. See Full Terms of Service.See Our Advertisement/Sponsored Stock Disclaimer. |
| | |
|
|
|---|
|
|
|
